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1. Introduction 
Many people worldwide suffer from bone defects due to trauma or disease. About 5-10% of 
football injury-related bone fractures, in addition to bone tumor resection and massive 
traumatic bone loss result in critical–sized bone defects that cannot regenerate 
autonomously (Cattermole et al., 1996; Low et al., 2004; Reuss et al., 2007 as cited in Porter et 
al., 2009). Usually small bone defects heal spontaneously but large defects cannot regenerate 
without intervention. There are several options for the reconstruction of large bone defects 
that include bone grafts (autograft, allograft and xenograft) as well as bone constructs 
created by bone tissue engineering principles.  
Among these different strategies, bone grafts from healthy donors have been used as  
therapies for decades, but nowadays they are used less due to inherent limitations 
associated with their application. For example, autografts are usually obtained from the iliac 
crest (Porter et al., 2009) and have been used in clinics for a long time. However some 
disadvantages, including supply limitation, risk of donor site morbidity, pain, paresthesia, 
hematoma and inflammation, as well as the need for prolonged rehabilitation (For review 
see Heary et al., 2002; Krelow et al., 2007; Maddela et al., 2010; Nakajima et al., 2007) limit 
their applications. Allografts, on the other hand, are the other option that may be chosen for 
bone defect regeneration. This type of bone graft can be derived from viable or sterilized 
non-viable (cadaver) human sources. Orthopedic allografts exhibit certain drawbacks by 
transmitting donor pathogens to the recipient body and triggering host immune responses 
(For review see Hou et al., 2005 and Nishida et al., 2008). Xenografts obtained from non-
human sources may be considered as the other alternative for reconstructing bone defects, 
but this is a last resort which may be taken because it is not an approved option in 
transplantation, owing to the obvious risk of viral and disease transmission, infection, 
toxicity and immunogenicity as well as rejection by the recipient’s body (For review see 
Laurencin et al., 2008; Yang et al., 2007).  
Concerns associated with applications of bone graft for critical size bone defects have 
challenged scientists to search for suitable options. Attempts to replace appropriate 
substitutes for bone graft have resulted in opening a new window in modern regenerative 
biomedicine and the emergence of bone constructs elaborated by tissue engineering 
principles. The term tissue engineering is defined as the application of the principles and 
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methods of engineering and life science toward fundamental understanding of structure-
function relationship in normal and pathological mammalian tissues and the development 
of biological substitutes for the repair or regeneration of tissue or organ function (Persidis 
1999; Chapekar et al., 2000). To develop biologic substitute tissue engineering uses three 
building blocks including scaffold, cells and growth factors. Each of these elements alone 
can promote tissue regeneration but constructs fabricated with the use of component 
combination would be more effective. The objective of the present chapter is therefore to 
describe bone construct fabricated with tissue engineering principles for bone regeneration. 
Among cellular candidates, mesenchymal stem cells (MSCs) possess some characteristics 
that make them more appropriate for bone tissue engineering. Hence, the focus of the 
current chapter is MSC-based bone constructs.  
2. Mesenchymal stem cells as cellular candidates for bone engineering 
Bone constructs typically consist of three elements: scaffolds, growth factors and cells. 
Several cell types can potentially be used as cellular material for elaborating a bone 
construct. In this section, commonly used cells with potential applications in the field of 
bone engineering will be summarized, followed by special focus on MSCs.  
2.1 Osteoblastic cells 
Osteoblastic cells may seem to be more appropriate for bone engineering because they are 
resident cells in natural bone and can be utilized at autogenic settings. In bone engineering 
strategies, osteoblastic cells are usually obtained from biopsies taken autologously from 
patient´s bone. Despite of this obvious advantage, there are some concerns with the use of 
osteoblasts in the process of bone engineering. Osteoblasts are present in limited numbers in 
bone biopsies since bone is indeed a tissue rich in ECM rather than cells. Furthermore, tissue 
engineering strategies need considerable cell numbers, however osteoblast proliferation is 
slow (Bruder et al., 1999; Heath et al., 2000). For these reasons stem cells having enormous 
proliferative capacity are preferable.   
2.2 Embryonic stem cells  
Embryonic stem cells (ESCs) are pluripotent cells derived from a blastocyst inner cell mass. 
Murine ESCs were described in 1981 (Evans et al., 1981) and human ESCs introduced in 
1998 (Thomson et al., 1998). Their indefinite self-renewal potential, differentiation capacity 
to all three germ layers, and osteoblastic cells in particular ( Arpornmaekilong et al., 2009; 
Hwang et al., 2009a; Warotayanont et al., 2009 as cited in Seong et al., 2010) have persuaded 
scientists that ESCs could be appropriate for clinical applications. ESCs have the 
characteristics of self-renewal as long as they are exposed to a feeder cell layer or leukemia 
inhibitory factor (LIF). Differentiation initiates upon removal of the feeder cell layer or LIF, 
resulting in the formation of three dimensional cell aggregates known as embryoid bodies 
(EBs). These EBs can regionally differentiate into derivatives of three germ layers: 
mesoderm, ectoderm and endoderm (Itskovitz-Eldor et al., 2000 as cited in Seong et al., 
2010). Generally, for osteogenic induction of ESCs, EBs or single cells from EBs are replated 
and induced by beta-glycerophosphate, ascorbic acid and vitamin D3 (Buttery et al., 2001; 
Kawaguchi et al., 2005; Woll et al., 2006 ). Thus ESCs can be a potential stem cell source to 
fabricate bone-like tissue constructs in the field of tissue engineering; however, 
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immunologic incompatibility and the possibility of teratoma formation in transplantations 
as well as certain ethical concerns make scientists hesitant to use them as cellular materials 
with which to fabricate bone construct for bone regeneration (Undale, 2009). 
2.3 Induced pluripotent stem cells  
Because of the above-mentioned concerns regarding ESCs, scientists have tried to establish 
ESC-like stem cells, known as induced pluripotent stem cells (iPSCs) from somatic cells by 
plasmid or adenovirus-based transduction ( Takahashi and Yamanaka, 2006, Park et al., 
2008, Kang et al., 2009 as cited in Feng et al., 2010). Actually, iPSCs are patient-specific ESCs 
without ethical concerns that do not trigger an immune response (Feng et al., 2010). The 
differentiation potential of these cells into various cell lineages, such as neural cells, 
cardiomyocytes and hematopoetic cells  as well as osteoblasts have been confirmed (Hanna 
et al., 2007; Wernig et al., 2007). Despite this prominent capability, there is an important issue 
which needs to be considered before their clinical applications. The method by which iPSCs 
are generated, i.e. through plasmid or adenovirus-based transduction is a main concern.  
2.4 Mesenchymal stem cells  
Among stem cells, mesenchymal stem cells (MSCs) seem to be more suitable for bone 
engineering compared to ESCs, iPSCs or osteoblastic cells due to several characteristics that 
they possess. First, the osteogenic differentiation potential of MSCs is the first differentiation 
capacity reported at the time MSCs were discovered. Today, it is one of the most obvious 
characteristics of MSCs which is maintained for an extended time. Secondly, autologous MSCs 
are easily accessible from patient's multiple tissues, including bone marrow aspirates. 
Additionally, because of MSCs ability to modulate immune responses, the use of allogeneic 
MSCs may be feasible without a substantial risk of immune rejection (Undale et al., 2009).  
2.4.1 Characteristics of MSCs 
MSCs are defined as non-hematopoietic cells derived from bone marrow as well as other 
mesenchmal tissues. These cells possess two important capacities: the potential to self-renew 
for a relatively long time and the ability to differentiate along multiple cell lineages 
including bone, cartilage and adipose cells.  MSCs express many surface antigens including 
STRO-1, CD105, SH3, CD29, CD44, CD71, CD90, CD106 and CD124 (for review see Pittenger 
et al., 1999; Colter et al., 2001).  Besides bone marrow, multiple tissues have been reported to 
contain MSCs including adipose tissue (Dragoo et al., 2003), trabecular bone (Noth et al., 
2002), periosteum (Fukumoto et al., 2003), synovial membrane (Wickham et al., 2003), 
skeletal muscle (Jankowsk et al., 2002), as well as teeth (Miura et al., 2003). 
Cohnheim, a German pathologist, initially suggested the presence of MSCs when he 
attempted to study wound healing in rabbits. By intravenous injection of non-soluble aniline 
stain, Cohnheim could detect some stained cells at the site of the wound which had been 
experimentally created in the animal’s distal limb. He concluded that the stained fibroblastic 
cells were derived from bone marrow and transferred to the wound site via the circulatory 
system (Prockop, 1997; Ross, et al., 1970). Since then, experimental studies on bone marrow 
transplantation have confirmed the osteogenic and chondrogenic differentiation capacities 
of bone marrow cells, but no one could clearly indicate the exact responsible cell types 
(Friedenstein et al., 1966; Petrakova et al., 1963). Finally, Friedenstein et al. have determined 
that the osteo/chondrogenic differentiation potential of bone marrow is due to the existence 
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of a fibroblastic population referred to as colony forming unit-fibroblasts (Friedenstein et al., 
1973). Thus far, these fibroblast-like cells have been referred to as marrow stromal cells; 
marrow progenitor cells (MPCs) and marrow stromal fibroblasts (MSFs), as well as 
mesenchymal stem cells (MSCs). MSC is the more frequently used nomination particularly 
in recently published investigations. 
MSCs occur in low quantity in bone marrow aspirate and constitute approximately 0.001%-
0.01% of the entire bone marrow cells. In spite of their limited numbers, MSCs can easily be 
expanded through standard culture techniques. The expansion of these cells is strongly 
dependent on the bovine serum content of the culture media. The cells assume spindly-
shaped morphology upon cultivation. MSCs primary culture has been reported to be 
heterogeneous and contains multiple colonies with various differentiation capacities. 
Pittenger et al., in 1999, have shown that nearly one third of these colonies have osteogenic, 
adipogenic and chondrogenic differentiation potentials and the other two thirds exhibit 
either bipotent or unipotent capacity to differentiate into osteogenic/chondrogenic and 
adipogenic lineages, respectively (Pittenger et al., 1999). In addition to differentiating into 
bone, cartilage and adipose cells, MSCs have been reported to possess differentiation 
capacity along non-mesenchymal cell lineages such as neurons, keratinocytes, liver, intestine 
and kidney epithelial cells (for review see Sugaya 2003; Chapel et al. 2003). This property is 
referred to as MSCs plasticity or transdifferentiation.  
2.4.2 Osteogenic differentiation potential of MSCs  
Osteogenic differentiation of MSCs is a complex process in which various environmental 
factors are involved. Dexamethasone, ascorbic acid and beta glycerol phosphates are the 
most commonly used chemicals that promote in vitro osteogenic differentiation of MSCs. 
Among these compounds, dexamethasone plays a pivotal role such that in its absence, no 
differentiation occurs in human MSC culture (Porter et al., 2003). Ascorbic acid, on the other 
hand, has been found to be an important but not necessary component of osteogenic 
medium. The addition of ascorbic acid into osteogenic medium results in enrichment of the 
deposited matrix with collagen (Choi et al., 2008). Beta glycerol phosphate, as a phosphate 
enriched organic compound, plays some role in matrix mineralization (Coelho et al., 2000). 
Besides these three routinely used compounds, hormones and growth factors have 
osteogenic effects on MSCs differentiation. These include 1, 25-di-hydroxyvitaminD3 (vitD3) 
(Rickard et al., 1995), estrogen (Holzer et al., 2002), leptin and parathyroid hormone (Holzer 
et al., 2002), prostaglandin E2 (Scutt et al., 1995), sonic hedgehog (Spinella-Jaegles et al., 
2001), IGF-1 (Koch et al., 2005), BMP-2, 4, 6, 7 (Gori et al., 1999; Diefenderfer et al., 2003; 
Gruber et al., 2004), FGF (Jaiswal et al., 2000), as well as bio- and lithium chloride (de Boer et 
al., 2004; Eslaminejad et al., 2008).  
Each osteogenic factor inserts its effect through a distinct signaling pathway. Some of these 
pathways, such as the dexamethasone pathway, are unknown whereas others are 
recognized to some extent. For example, BMPs mediate their osteogenic effects through the 
BMP signaling pathway, via activation of smad transcription factors (Massague et al., 2000) 
and parathyroid hormone induces the expression of osteogenic genes via the G-protein 
coupled receptor signaling pathway (Carpio et al., 2001).  
Induction of the above-mentioned signaling pathways ends consequently in expression of 
some specific signaling proteins and specific osteoblastic transcription factors. Core binding 
factor alpha 1 (Cbfa1), also referred to as Runx2, is the most important transcription factor 
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involved in osteogenesis (Yamaguchi et al., 2000). This transcription factor induces the 
expression of different bone-related genes including osteocalcin, osteopontin, bone 
sialoprotein and the parathyroid hormone receptor (Ducy et al., 2000). Furthermore, osterix 
is the other transcription factor reported to be expressed upon commitment of cells toward 
osteogenic differentiation (Tu et al., 2006).  
2.4.3 Self-renewal in MSCs 
Self-renewal and differentiation potential are hallmarks for stem cells. The ability of a cell to 
produce similar replicates in a defined period of time via mitosis is called self-renewal.  In 
this type of mitosis, genetic properties and karyotype of daughter cells remain intact, the 
same as the mother cell. There are two models that explain stem cell self-renewal property: 
symmetric and asymmetric cell division. In symmetric cell division, the stem cell divides 
into two daughter cells, similar to the mother cell, which have the capacity to differentiate 
under appropriate conditions (Potten and Loffler, 1990). In asymmetric cell division, each 
stem cell divides into one stem cell and one progenitor cell. The stem cell continues to divide 
and replenish the stem cell pool, while the progenitor cell differentiates under appropriate 
conditions (Sherely et al., 1995). Therefore, through this type of cell division, the number of 
stem cells remains intact.  
While identification the underlying molecular mechanisms of MSCs self-renewal would be 
beneficial to stop replicative senescence in MSCs, this issue remains largely unknown. 
According to the literature, various cytokines and growth factors such as LIF (Jiang et al., 
2002), FGFs (Zaragosi et al., 2006) and Wnt proteins (Kleber et al., 2004) have, however, 
some roles in keeping MSCs in a stemness state.  
2.4.4 Immunomodulatory properties of MSCs 
The immunomodulatory property of MSCs is one of the most considerable issues in the field 
of regenerative medicine. Numerous evidences exist on the suppressive effects of MSCs on 
immune cell activity.  Co-culturing MSCs with T-lymphocytes results in the inhibition of T 
cell proliferation (Di Nicola et al., 2002). This  effect is believed to be mediated by secretion 
of soluble factors that include interleukin 10, prostaglandins and hepatocyte growth factor 
as well as TGF-beta or via direct cell to cell contact ( for review see  Bassi et al., 2011). 
Besides T-lymphocytes, MSCs insert their immunomodulatory effect by inhibition of B cell 
proliferation and antibody secretion (Rasmusson et al., 2007). Reportedly, they also suppress 
differentiation, maturation and activation of dendritic cells (Nauta et al., 2006 as cited in 
Bassi et al., 2011). Moreover, MSCs can suppress natural killer (NK) cell proliferation and 
change their phenotype, cytokine secretion and cytotoxic properties (Sotiropoulou et al., 
2006). MSCs express an intermediate level of MHC class I, very low levels of MHC class II 
and do not express costimulatory molecules (Klyushnenkova et al., 2005).  
Although the hypo-immunogenic properties of MSCs have roused medical interest to 
establish allogenic MSC banks for clinical application in the field of regenerative medicine, 
there remains one important question that must be taken into consideration: Do MSCs keep 
their immunomodulatory properties even after differentiation? Liu et al. have used MSCs 
from a rabbit model to answer this question (Liu et al., 2006). Their results have shown that 
osteogenic differentiated MSCs did not express MHC class II in vitro; however, 
transplantation of the differentiated cells makes these cells lose their immunomodulatory 
properties in vivo.  
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3. MSC-based bone constructs 
As mentioned, bone construct fabricated using scaffolds, cells and growth factors would be 
appropriate substitutes for bone grafts. Cells were previously described. In this part of the 
chapter, scaffolds and growth factors will briefly be considered and followed by some 
important issues in the field of bone engineering, including cell seeding onto scaffold, 
commonly-used bioreactors in bone engineering and the issue of the construct vascularity.   
3.1 Scaffolds 
Bone, as a dynamic and supportive tissue, is a nanocomposite structure. It is in fact a 
complex of well-organized inorganic–organic nanomaterials including hydroxyapatite [HA, 
Ca10 (Po4)6 (OH) 2)] and collagen fibrils arranged in a masterly order (Maddela et al., 2010). 
Within this biomaterial composite, osteocytes lie in cavities referred to as lacunae.  In bone 
tissue engineering, material scientists attempt to make biocompatible and biodegradable 
scaffolds with appropriate porosity, mechanical strength and hydrophobicity comparable to 
native bone materials (Lee et al., 2007 as cited in Maddela et al., 2010). Biocompatibility is 
the most important characteristic of scaffolds, which means that the scaffold material must 
not be toxic or promote inflammation upon transplantation. All scaffold degradation 
products should also be biocompatible. The scaffold must also be biodegradable meaning 
that it gradually degrades at the implantation site in harmony with bone regeneration in 
order to provide spaces for natural bone growth. Scaffold porosity is another characteristic 
that merits consideration in designing scaffolds. Incorporation of open and interconnective 
pores into the scaffold structure is essential in terms of cell growth and distribution, 
facilitation of vessel formation and diffusion of nutrient and waste products. The size of 
pores is recommended to be around 200-900 micrometers. If they are too small cells may 
adhere to the scaffold’s superficial part. Large pore size, on the other hand, compromises 
scaffold strength. Since bone construct should be implanted at the defective bone site where 
it must temporary support the fracture, therefore bone scaffolds must possess mechanical 
properties comparable to native bone. The scaffold’s surface property, in terms of chemical 
and topographical features, is a parameter that influences scaffold interaction with cells. 
Scaffolds must possess appropriate surfaces upon which cells can adhere, proliferate and 
differentiate.  
Materials used to fabricate bone scaffolds include natural and synthetic bioceramics, natural 
and synthetic polymers and composites of polymers with bioceramics. 
3.1.1 Bioceramics 
There are two categories of bioceramics: naturally occurring (i.e., coral hydroxyappatite) and 
synthesized (i.e., synthetic hydroxyapatite and tricalcium phosphate).   These materials  are 
widely used in medical trials, orthopedics (for review see Block et al., 2000; Heini et al., 2001; 
Katti et al., 2004; Taksali et al., 2004 as cited in Habraken et al., 2010)  and plastic surgery 
(Gladstone et al., 1995) due to their high mechanical strength and body response (Habraken 
et al., 2010). In particular, hydroxyapatite-based calcium phosphate compounds and 
bioactive glass are a focus of interest for bone engineering because they possess 
osteoconductive properties (LeGeros et al., 2002; Kenny et al., 2003). There are, however, 
several disadvantages that limit the application of bioceramics in the tissue engineering 
field. These materials possess low biodegradability and they bind strongly to growth factors 
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such as bFGF and TGF-β3, releasing them at very slow rates unsuitable for clinical 
applications (Habraken et al., 2010). Moreover, ceramics possess low tensile strength and are 
very brittle. 
3.1.2 Polymers  
As a whole, based on origin, polymers can be divided into two categories: natural and 
synthetic (Lee et al., 2007). The most widely used natural polymers in bone tissue 
engineering include collagen, alginate and chitosan. Collagen can be easily solubilized in 
physiological fluid (Lee et al., 2007; Maddela et al., 2010). Beside this advantage, 
immunogenecity, hard processing and the possibility of pathogen transmission are the most 
prominent disadvantages of natural polymers. Among natural polymers, collagen type I is 
very interesting since it is the pivotal organic component of bone matrix that is actively 
secreted by osteoblast cells (Lee et al., 2007). Although this protein in the form of a gel, 
nanofiber, porous scaffold and film is biocompatible, it cannot tolerate mechanical forces 
and consequently undergoes degradation at the implant site. Thus, natural polymers are 
rarely used alone.  
Synthetic biodegradable polymers include polyglycolic acid (PGA), polylactic acid (PLA), 
polylactic-co-glycolic acid (PLGA), polycaprolacton (PCL), polypropylene fumarate (PPF), 
polycaprolacton fumarat and polycaprolacton diacrylate. Synthetic polymers are 
appropriate options as bone engineering scaffolds because they can be fabricated in large 
quantities, the risk of infection and toxicity is less compared to natural polymers. In 
addition, they possess less immunogenicity. Other advantages of synthetic polymers are 
their mechanical, physical, and chemical properties, elastic module, acidity and 
hydrophilicy which can easily be adjusted to match bone tissue. The disadvantages of 
synthetic polymers however include their very low strength that worsens with the 
introduction of pores to form tissue engineering scaffolds. Furthermore, most of these 
materials are considered non-osteoconductive (Behravesh et al., 1999; Middletone et al., 
2000).  
3.1.3 Composite scaffolds 
The composite strategy has emerged with the purpose of seeking better scaffolds for bone 
tissue engineering. In this strategy, the objective is to combine bioceramic material with 
polymers to make use of the advantages of each biomaterial. In this manner, many polymer-
based scaffolds that consist of bioactive bioceramics such as hydroxyapatite/PLLA have 
been produced (Zandi et al., 2010; Eslaminejad et al., 2007). In composite scaffolds, 
bioceramics serve to make the scaffold osteoconductive and provide reinforcement whereas 
the polymer serves to solve the problem of poor degradability, low tensile strength and 
brittleness of ceramics (Wang 2005). 
3.2 Growth factors 
Bone normal development involves a variety of hormones, cytokines and growth factors. 
These biomolecules regulate osteoprogenitor proliferation, migration and differentiation in 
a controlled manner (for review sees Kain et al., 2005, Schmidmaier et al., 2006). The 
following growth factors have been reported to play some role in bone differentiation; hence 
they can be used in bone engineering. 
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3.2.1 Bone morphogenetic protein  
Urist et al. in 1965 have reported that decalcified bone can induce the formation of ectopic 
bone; therefore they concluded that osteoinductive molecules could be present in the bone 
matrix and direct the differentiation of precursor cells into bone cells. Later these molecules 
were called bone morphogenetic proteins (BMPs) and are members of the TGF-beta 
superfamily. BMP-2, 4 and 7 are the main members of this category whit a considerable 
effect on the induction of bone formation (Kirker et al., 2000; Yoon et al., 2004). 
3.2.2 Insulin-like growth factor 
Insulin-like growth factor (IGF) induces proliferation and chemotactic migration of many 
types of cells. This growth factor has an important role in bone metabolism (Matsuda et al., 
1992) especially at the time of fracture healing (Chen et al., 2006).  
3.2.3 Fibroblast growth factor 
The fibroblast growth factor (FGF) family has a conflicting role in osteogenesis and bone 
healing. While some authors have reported a positive effect of FGF-2 on bone healing 
(Kawaguchi et al., 1994; Kato et al., 1998), others have indicated that bFGF induces osteoclast 
formation (Nakagawa et al., 1999).  
3.2.4 Vascular endothelial growth factor 
This growth factor exerts its effects through induction of vascularization which in turn plays 
an important role in bone growth and development (Lee et al., 2007). Vascular endothelial 
growth factor (VEGF) also supports the survival and activity of bone-forming cells (Hsiong  
et al., 2000)  as well as migration and differentiation of primary human osteoblasts (Mayr-
Wohlfart  et al., 2002; Orlandini et al., 2006). 
3.2.5 Growth factor delivery in bone tissue engineering 
In order to have an efficient bone healing procedure, selection of suitable vehicles and 
types of bioactive molecules are crucial. There are two types of immobilization methods 
for binding of bioactive molecules to the carrier: non-covalent (physical entrapment, 
surface adsorption, affinity binding or ionic complexation) or covalent (chemical 
conjugation).  
In bone engineering either polymeric or bioceramic carriers can be used to deliver growth 
factors to the site of the tissue defect. PLA and PGA are two well- known polymers of alpha-
hydroxyl esters and copolymers of these monomers (PLGA) are good vehicles to carry 
osteoinductive factors (for review see Behravesh et al., 1999; Saito et al., 2001a, as cited in 
Lee et al., 2007). Calcium phosphate cement (CPC), bioactive glasses, HA and beta-TCP are 
non-polymeric, inorganic materials that have also been processed to deliver growth factors 
such as TGF, beta1 and BMPs (for review see Hedberg et al., 2005; Laffargue et al., 1999; 
Ripamonti et al., 1992).  
The design of a delivery system, in the form of three-dimensional matrices, injectable gels, 
and micro/nano particulates determines release kinetics and stability of growth factors in 
constructs (Lee et al., 2007). Furthermore, physical structure and degradation time of 
polymers are important parameters to determine the release behavior of growth factors 
(Holland et al., 2006, as cited in Lee et al., 2007).  
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3.3 Cell seeding onto scaffold surfaces 
Bone construct is a term used to denote an engineered material that consists of different 
components, including scaffold/growth factors, scaffold/cells and scaffold/cells/growth 
factors. In the previous section incorporation of growth factor into the delivery vehicle 
(scaffold) was summarized. In the following sections, seeding of cells on scaffold surfaces - a 
crucial procedure in bone construct fabrication is discussed.  Indeed, good cell-to-cell 
contact and acceptable dissemination of the cells within a scaffold are the results of an 
appropriate seeding procedure.  These parameters have extensive impact on uniform well-
developed bone tissue regeneration and mineralization after construct transplantation (Holy 
et al., 2000; Ishaug- Riley et al., 1998).  
3.3.1 Static cell seeding method 
Although the addition of the cell suspension onto a scaffold (static cell seeding system) is 
the most simple and frequently used method (Scaglione  et al., 2008; Li et al., 2001), it is not a 
good approach for  a well-elaborated bone construct with high cell density and homogenous 
cell distribution. This method is associated with a low seeding efficiency of approximately 
10-25% (Roh et al., 2007) and a low rate of cell penetration inside the scaffold (Mo et al., 
2004; Ravi et al., 2009; Ma, 2008). Even penetrated cells are unable to establish attachment 
with scaffold surfaces.  
3.3.2 Dynamic cell seeding  
Dynamic cell seeding process is a type of cell seeding usually performed with bioreactor 
systems. It can be categorized into two different systems: rotational seeding based on the 
use of hydrostatic forces (Hsu et al., 2005; Nasseri  et al., 2003) or vacuum seeding using 
pressure differentials (van Wachem  et al., 1990; Williams  et al., 2004). Cell seeding yields 
by these techniques range from 38 to 90% and 60 to 90%, respectively, compared to 10-25% 
for static seeding. Although the long seeding time in the rotational system and its bad 
impact on cell morphology limits its application, no adverse effects have thus far been 
reported for the vacuum seeding method (Gustavo et al., 2010).  
3.3.3 Magnetic cell seeding method 
Magnetic cell seeding is another technique proposed to efficiently incorporate cells inside 
scaffold porosity. This method involves the use of a magnetic force to attract magnetic 
nanoparticles attached to desired cells (Gustavo et al., 2010). There are two main approaches 
in this method. The first one involves the application of superparamagnetic monosized 
polymers such as dynabeads with the ability to bind specifically to a desired cell or protein 
and subsequent seeding of the cells in the scaffold by producing a temporary magnetic field. 
The efficiency of this method has been reported to be as much as 99% (Perea et al., 2006; 
Tiwari et al., 2003, as cited in Gustavo et al., 2010). The second approach is to first label 
desired cells by cationic liposomes that contain superparamagnetic iron oxide particles, then 
seed them into a scaffold by the administration of a transient magnetic force. The efficiency 
of this protocol has been reported to be as high as 90% (Ito et al., 2004; Shimizu et al., 2007 as 
cited in Gustavo et al., 2010). Rapid graft production and reproducible results are the main 
advantages of using this method in tissue engineering; albeit cell viability, cell morphology, 
as well as the fate of magnetic particles in the body and their adverse effects on other tissues 
need further evaluation (Gustavo et al., 2010). 
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3.4 Bioreactors  
Bioreactors, as containers or vessels, have long been used to hold microorganisms and 
different types of eukaryotic cells for the purpose of harnessing their natural biochemical 
processes in the production of drug and recombinant proteins. The main reason to use 
bioreactors in industry and medicine is the large scale production of desired products at an 
optimal level of gas, nutrients, temperature and tolerable amount of waste products for an 
extended period of time (Haasper et al., 2008). Bioreactors have also found some application 
in the bone tissue engineering field due to valuable advantages they offer toward producing 
optimal bone construct. Bioreactor systems help bone tissue engineering in several ways. 
The bioreactor cell culture process is automated. In this manner, the risks of cellular/ 
microbial contamination, labor intensity and laboratory costs during cell expansion and 
differentiation are minimized (Andrew et al., 2011). Furthermore, automated cell cultures 
have the advantages of improved cell seeding efficiency (Wendt et al., 2003) as well as cell 
proliferation (Grayson  et al., 2008). Bioreactors can be used to improve nutrition of the cells 
located in the deep areas of the constructs during the culture period. With the use of an 
appropriate bioreactor system, different stress protocols (such as shear) can be applied on 
bone construct. There are three main commonly used bioreactor systems in bone tissue 
engineering: spinner flask, rotating wall and perfusion system.  
3.4.1 Spinner flask 
This bioreactor is a commonly used system in bone tissue engineering (for review see 
Ichinohe et al., 2008; Sikavitsas et al., 2002). It is composed of a vessel containing culture 
medium in which the tissue construct is suspended through a wire. A rotating magnetic bar 
causes the culture medium to agitate (Andrew et al., 2011). This system is more efficient in 
terms of bone differentiation compared with static and rotating wall culture systems. In 
spite of this positive point, the spinner flask possesses a deficiency regarding construct 
nutrition (Sikavitsas et al., 2002). One way to improve nutrient and waste product transport 
in and out of the construct is to increase the amount of rotation in the magnetic bar but this 
may lead to increased turbulent flow which in turn increases shear stress on the construct. It 
should be mentioned that although shear stress produced in the bioreactor has a positive 
influence on bone differentiation and mineralization (Bancroft et al., 2002, 2003; Bilodeau et 
al., 2006), exceeded stress may cause cellular damage. For this reason, there must always be 
a balance between nutrient transport efficiency and shear stress within the spinner flask. 
3.4.2 Rotating wall bioreactors 
This type of bioreactor is composed of two cylinders. The smaller cylinder is a stationary 
one inside the system and provides for gas exchange, while the outer one rotates. The cell- 
seeded scaffold moves freely in the medium between these two cylinders (Andrew et al., 
2011; Sikavitsas et al., 2002). It is believed that this system is not a very good culture system 
in bone tissue engineering due to the haphazard movement of the scaffold in the system, 
collision with the wall of the bioreactor and the low level of shear stress provided by this 
regime (Andrew et al., 2011). 
3.4.3 Perfusion bioreactors 
This system is a widely-used bioreactor in bone tissue engineering (for review see Bancroft  
et al., 2003; Gomes  et al., 2003; Grayson et al., 2008; Sikavitsas et al., 2005). This bioreactor is 
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composed of a perfusion cartridge connected to a pump and a medium reservoir through a 
tubing circuit. The perfusion cartridge surrounds the scaffold tightly, thus the medium 
cannot flow around the scaffold so it perfuse directly through the scaffold (Andrew et al., 
2011). There are various types of this bioreactor. Those commonly used in bone tissue 
engineering include the flow perfusion culture bioreactor (for review see Bancroft et al., 
2002, Gomes  et al., 2003; Grayson et al., 2008; Sikavitsas et al., 2005), radial channel 
perfusion system (Grayson  et  al., 2008) and direct perfusion bioreactors (for review see 
Janssen et al., 2006a, 2006b, 2010). Use of the perfusion bioreactor improves nutrient and 
waste product transport within the construct. Cell loading efficiency is also improved in 
these systems since they are designed in such a way that the flow direction is repeatedly 
changed. Moreover, shear stress produced in this bioreactor enhances osteogenic 
differentiation of the loaded cells.  
3.5 Vascularization 
Bone construct usually encounters nutritional limitation due to a lack of microvasculature 
which occurs at two stages, during in vitro culture and the early days after implantation.  As 
previously described, in vitro nutritional limitations can somewhat be improved with the 
application of an appropriate bioreactor system. To overcome nutritional limitation during 
the early days of implantation several strategies have been developed with the objective of  
inducing angiogenesis inside the construct.  
3.5.1 Angiogenic growth factors 
One strategy is to use growth factors known to promote angiogenesis when fabricating bone 
construct. According to the literature, angiogenic growth factors include VEGF (Mayr-
Wohlfart  et al., 2002; Deckers et al., 2000), FGF (Saadeh et al., 2000), BMP-2, endothelin-1 
(ET-1) (Von Schroeder et al., 2003; Bouletreau et al., 2002a), PDGF-BB (Bouletreau et al., 
2002b), IGF and TGF-beta (Bouletreau et al., 2002b; Saadeh et al., 1999). VEGF has a direct 
effect on angiogenesis whereas the others exert their effect indirectly through regulation of 
VEGF secretion. Although VEGF plays a pivotal role in angiogenesis, unfortunately high 
doses of this recombinant protein are necessary to reach an optimal level of angiogenesis 
(Barralet et al., 2009).  
3.5.2 Design and architecture of the scaffold 
Design and architecture of a bone scaffold facilitates blood vessel formation in the fabricated 
construct. For example, nano/micro fiber combined scaffolds have been shown to promote 
endothelial cell migration and organization into capillary-like structures within the scaffold 
(Santos et al., 2008 as cited in Marina et al., 2010). The inclusion of a network with 
vasculature geometry in a biocompatible polymer using microfabrication techniques has 
been reported as an alternative way to create vessel-like structures in scaffolds. It should be 
mentioned that such methods are commonly used in developing a vasculature tree in soft 
organs rather than hard tissues such as bone (Marina et al., 2010). 
3.5.3 Co-culture system 
Since endothelial cells are able to establish microcapillary-like structures, the use of them in 
bone construct can be considered an alternative strategy to promote vessel formation inside 
the construct. For this purpose endothelial progenitor cells (EPCs) from bone marrow may 
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be preferred.  There are two types of EPCs, early and late (Veleva et al., 2008). Early cells 
appear within 4-7 days in culture and exhibit some endothelial as well as monocytic 
properties with restricted proliferative capacity.  In contrast, late cells are those that appear 
2-3 weeks after culture initiation and keep their expansion potential for a long time. 
According to investigations, while early cells contribute in neovascularization indirectly 
through cytokines and matrix metalloproteinase-8 (MMP-8) secretion, late cells contribute to 
vessel formation as building blocks as well as through MMP-2 secretion (Yoon et al., 2005, as 
cited in Marina et al., 2010). 
3.5.4 Microsurgery strategies 
Microsurgery techniques offer another approach to create blood vessel inside bone 
construct. Two of the most popular microsurgery methods for creating vascularized bone 
construct include flap fabrication and the creation of an arteriovenous loop (Kneser et al., 
2006). In flap fabrication, bone construct including the scaffold, cells and growth factors pre-
transplants in a rich vascular bed (i.e., muscle) from which some blood vessels grow into the 
construct (Scheufler  et al., 2008; Polykandriotis  et al., 2007). Donor-site morbidity and two 
surgical interventions are two disadvantages of this method (Ren et al., 2008). In the 
arteriovenous loop method, vascularization of the porous scaffold is performed by 
implantation of an arterovenous loop around the construct (Kneser et al., 2006).  
4. Bone regeneration promoted by MSC-based bone constructs 
As mentioned earlier, large bone defects need clinical intervention for regeneration. For this 
purpose bone construct fabricated using tissue engineering principles is considered as a 
promising choice. Different types of bone constructs will be described followed by some 
examples in which MSC-based bone constructs have been used to regenerate bone defects in 
either animal models or humans.  
4.1 Types of bone construct based on constituting components  
Past investigations regarding bone regeneration have used the following constructs which 
differed in terms of their constituting elements: scaffold, cells, scaffold/growth factor, 
scaffold/cells, scaffold/cells/growth factor and scaffold/DNA. Scaffold alone is more 
suitable for small bone defects and usually comprised of tricalcium phosphate ceramics. Cell 
constructs involve the administration of MSCs in an injectable form with or without genetic 
manipulation. Scaffold/growth factor constructs are constructs in which growth factors are 
linked chemically or physically to a carrier or scaffold. Scaffold/MSCs constructs are the 
most frequently used one in tissue engineering and many studies have been designed with 
this model. Sometimes the scaffold/MSC construct contains transfected cells and this indeed 
is a combination of gene therapy and tissue engineering. Scaffold/cells/growth factor 
construct, on the other hand are rarely used. An excellent example of such construct is 
Gronthos´ study (see below). Finally, the scaffold/DNA construct involves loading a 
scaffold by a DNA construct, usually in the form of plasmid DNA (Bonadio et al., 1999). 
4.2 MSC-based bone construct transplantation in animal models 
Before clinical application, a newly developed bone construct should be tested in animal 
models in term of its functionality. By pre-clinical studies scientists understand whether 
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regeneration occurs due to the presence of MSCs in bone constructs or the 
osteoconductive/osteoinductive properties of the scaffold/growth factor. Among different 
preclinical models, large bone defect models are more commonly used since they are the 
type of defects problematic in the field of orthopedics as well as maxillofacial surgery (for 
review sees Perka et al., 2000). Various worldwide animal and clinical studies have been 
undertaken to cure this type of bone disease. Following are some examples of animal model 
studies that have used MSC-based constructs.   
4.2.1 MSCs alone 
An example of the application of MSCs in an animal bone defect model is a study conducted 
by Tsuda et al. who used MSCs transfected with BMP-2 to improve an osteoporetic disorder 
of aged rats (Tsuda et al., 2005).  
4.2.2 Scaffold/MSCs 
The application of bone constructs that consist of scaffold/MSCs is a common strategy to 
heal large bone defects, also referred to as critical sized defects in animal models. In most 
studies bioceramics are the biomaterial of choice.  Kadiyala et al. have used autologous bone 
marrow-derived MSCs seeded onto ceramic scaffolds to regenerate an 8-mm 
experimentally-created defect in the rat femora. After eight weeks, bone formation was 
detected in the defective area (Kadiyala et al., 1997b). Similar animal studies have also been 
reported for canine and sheep models using scaffold/MSCs constructs (For review see 
Arinzeh et al., 2003; Kon et al., 2000). Application of varying ceramics in different ratios 
would be very crucial for fabricating a good construct. For example, Buruder et al. have 
fabricated MSC-based scaffolds comprised of 35% beta tricalcium phosphate and 65% 
hydroxyapatite which was implanted in a 21-mm experimentally-created segmental defect 
in the canine femur. They observed good integration of the construct with the host bone 
(Bruder et al., 1998). Using ceramic biomaterials we have also conducted some 
investigations. According to our studies, the use of rat MSCs in conjunction with natural 
scaffolds (i.e., Bio-Oss or  human deproteinized and decellularized bone tissue) could 
enhance bone regeneration in rat calvarial defects more than platelet-rich plasma treatment 
(Khojasteh et al., 2009). In another study, we have compared the bone regeneration capacity 
of HA/TCP/MSCs with Bio-Oss/MSC constructs. Our results have shown the enhanced 
bone regeneration potential of HA/TCP/MSCs construct in a canine full-thickness alveolar 
defect model (Jafarian et al., 2008) compared with Bio-Oss/MSCs constructs. 
Other research groups have studied the regenerative role of MSCs in combination with 
polymeric scaffolds in animal bone defects. For example, in a study by Holy et al., 1.2 cm 
bone defects in a rabbit femur were regenerated by using MSCs-loaded PLGA scaffolds. 
Their results have shown significant bone regeneration in MSC-based PLGA scaffolds 
compared with PLGA alone (Holy et al., 2003).  
The composite scaffold/MSCs construct has also been tested in animal bone defects. For 
example, Diao et al. have manufactured a construct comprised of umbilical cord blood 
MSCs seeded on composite scaffold consisting of hydroxyapatite, PLLA and collagen. The 
composite, then, was implanted subcutaneously into SCID mice. Twelve weeks later, well- 
promoted bone formation was observed in histological sections (Diao et al., 2009).  
MSCs derived from sources other than bone marrow have been successfully applied to 
regenerate bone defects in combination with scaffolds. For example, the construct made of 
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porous cylindrical PLA scaffolds and autologus adipose-derived stem cells have been 
reported to successfully regenerate skull defects in New Zealand white rabbits (Bella et al., 
2008). Similarly, Jang et al. have noted the efficiency of construct comprised of beta TCPs 
and canine umbilical cord blood MSCs in canine cortical defect regeneration (Jang et al., 
2008).  
4.3 MSC- based bone construct in clinical trials 
The ultimate objective of elaborating bone construct using principles of tissue engineering is 
to find an appropriate substitute for autologous bone graft which is considered the golden 
standard for regeneration of bone defects. The excellent regenerating effects of autologous 
bone graft may be related to its osteoconductive, osteoinductive and osteogenic capacities. 
Constructs fabricated by engineering principles using all three main building blocks have 
potentially all components necessary for real representation of autologous bone graft.  
In bone construct, MSCs can be present either in an undifferentiated or differentiated 
state. Using MSCs as undifferentiated cells may have the disadvantage of their unwanted 
differentiation into non-bone cells where they are supposed to generate osteogenic cells. 
On the other hand, transplantation of MSCs as fully differentiated cells would be an 
alternative way to deliver cells into a bone defect. This requires long-term culture of the 
cells which is undesirable in a cell therapy strategy. Both strategies have been used in 
clinical trials.  
At the moment, multiple clinical trials have been accomplished on human problematic bone 
lesions. Several others are ongoing and registered at http://clinicaltrials.gov, the official 
clinical trials  website. In this regard, Royan Institute has registered a number of clinical 
trials regarding nonunion fractures, delayed union, bone cyst and distraction osteogenesis, 
using MSC-based bone constructs. In the following section some accomplished trials will be 
noted which are categorized according to the composition of the construct used.   
4.3.1 MSCs alone 
One well known example of the use of MSCs alone to regenerate osteogenic defects is in the 
treatment of osteogenesis imperfecta (OI), a heterogenous group of inherited disorders. 
Horwitz et al. have reported a trial in which allogenic bone marrow cells (from HLA- 
identical or single- antigen-mismatched siblings) have been intravenously infused into 
children with severe OI. According to their findings, there have been signs of improvement 
after transplantation as they observed a reduced number of osteocytes, linearly organized 
osteoblasts, lamellar bone formation as well as mineralization in the trabecular bones of 
affected children. Although this study demonstrated osteoblastic differentiation of MSCs, 
the lack of reliable controls and the absence of a long follow up period were the weak points 
of this clinical study (Horwitz et al., 1999). To fulfill this trial, Horwitz continued his study 
in another project in 2001 in which seven children with OI were selected. Five received cell 
therapy while two were in the control group. Six months after transplantation, growth 
acceleration was observed in the treated group in comparison with control children 
(Horwitz et al., 2001).  
Another example of MSCs injection is with tibial achondroplasia and pseudoarthrosis in which 
distraction osteogenesis is necessary. To accomplish this, in vitro osteogenic differentiated 
marrow MSCs accompanied by platelet-rich plasma were injected into the distracted callus. 
After a period of time, healing was observed in treated patients (Kitoh et al., 2004).  
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4.3.2 Scaffold/MSCs/growth factor 
Constructs consisting of three components have rarely been utilized to regenerate human 
bone defects. An example is the work by Gronthos who has tried to regenerate 7-cm length 
mandibular defect generated due to tumor resection in a 56 year old patient. In this study, 
he designed a hollow titanium mesh, filled it with hydroxapatite, recombinant human BMP-
7 and MSCs, and transplanted it into the patient’s lathismus dorsi muscle in order to 
encourage ectopic bone formation and blood vessel ingrowth. Seven weeks later, 
vascularized bone construct was removed and implanted into the patient´s mandible. Four 
weeks post-transplantation, the mandible was functional and the patient could chew food 
(Gronthos, 2004).  
4.3.3 Scaffold/MSCs 
Scaffold/MSCs constructs are commonly used constructs in most clinical trials. There are 
several examples of such approaches in the literature. One such example is the work by 
Quarto et al. who have designed bone marrow MSC-loaded hydroxyapatite scaffolds to 
regenerate 7-cm length human bone defects. Two months after transplantation, a large 
callus formed in the defect site with integration of the construct into host bone (Quarto et al., 
2001). In a similar study, Morishita et al. have published successful bone tissue engineering 
approaches in the treatment of bone tumors by the implantation of authologous  MSCs-
loaded  hydroxyapatite scaffold (Morishita et al., 2006). Similarly Marcacci et al. have 
prepared constructs using autologous MSCs and hydroxyapatite scaffold, and have 
transplanted them into long bone defects in humans. Their trial was prominent since they 
had a prolonged follow up of 6-7 years. Using this method, they could detect good 
integration of the loaded scaffolds with surrounding bone, new vascular ingrowth and new 
bone formation inside the scaffold. Recovery of limb function was also reported and 
maintained after the 6-7 year follow up (Marcacci et al., 2007).  
5. Conclusion 
Bone constructs elaborated with tissue engineering principles are a promising substitute for 
autologous bone graft and have long been considered the golden standard for repair of large 
bone defects. Autologus bone graft owes its excellent repair effects to three crucial 
properties of osteoinduction, osteoconduction and osteogenesis. The building blocks that are 
used to fabricate bone construct impart three key properties as autologous bone graft (cells 
impart osteogenic property, scaffold cause osteoconductive and osteoinductive capacity and 
growth factors give osteoinductive potential). However, before tissue-engineered bone 
construct are to be routinely used in the clinic setting instead of bone grafts, several issues 
must be addressed. Although application of MSCs as cellular material facilitates the 
construct fabrication, there is still some issue with MSC preparation. MSC propagation is 
largely dependent on fetal bovine serum. Furthermore, natural bone is a composite of nano 
hydroxyapatite particles with collagen nanofibers which impart the tissue’s unique 
properties. Unfortunately developing a scaffold with similar properties is still challenging. 
Finally, perhaps the main challenge in the field of bone tissue engineering is formation of 
blood vessels inside the fabricated constructs. Several strategies including the addition of 
angiogenic growth factors and cells to the construct, angiogenic design and architecture of 
bone scaffold, and microsurgery techniques have been proposed to promote angiogenesis 
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inside the constructs. However, there is no reliable, reproducible and practical strategy in 
this developing field.  
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